Prognostic indicators in male breast carcinoma

Area of Science:

• Oncology
• Pathology
• Biomarkers

Background:

• Male breast cancer (MBC) is rare, necessitating research into prognostic factors for improved patient outcomes.
• Understanding the expression and significance of prognostic markers in MBC is crucial for tailoring treatment strategies.

Purpose of the Study:

• To investigate the relationship between various prognostic factors and clinical outcomes in a cohort of male breast cancer patients.
• To compare the frequency and prognostic significance of these markers with those observed in female breast carcinoma.

Main Methods:

• Immunohistochemistry was used to assess the expression of estrogen receptors (ER), progesterone receptors (PR), cathepsin D (CD), c-erbB-2, epidermal growth factor receptor (EGFR), and p53.
• DNA ploidy and proliferating cell nuclear antigen (PCNA) were evaluated using image analysis and cytometry.
• Clinical data, including lymph node and distant metastases, and survival rates were analyzed.

Main Results:

• High frequencies of ER (89.7%), PR (65.5%), and CD (86.2%) expression were observed.
• Aneuploid DNA content was found in 72.4% of cases, with a mean PCNA of 37.87%.
• Age ≥ 62 years was a significant unfavorable prognostic indicator (p = .004). Trends toward reduced survival were associated with lymph node metastases, ER/PR negativity, and aneuploid DNA content.

Conclusions:

• Prognostic factor expression in MBC is largely similar to female breast carcinoma, with notable exceptions in ER and CD frequency.
• Age is a significant clinical prognostic factor in male breast cancer.
• Further research is warranted to elucidate the full prognostic and therapeutic implications of these markers in male breast cancer.